Fintel reports that on January 30, 2025, Chardan Capital downgraded their outlook for CARGO Therapeutics (NasdaqGS:CRGX) from ...

CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) was downgraded by stock analysts at Chardan Capital from a “buy” rating to ...

Chardan downgraded Cargo Therapeutics (CRGX) to Neutral from Buy without a price target The company will be discontinuing the Phase II FIRCE-1 ...

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

Equities research analysts at Leerink Partnrs decreased their Q4 2024 earnings estimates for shares of Mind Medicine (MindMed) in a research note issued on Wednesday, January 29th. Leerink Partnrs ...

On Thursday, Chardan Capital Markets revised its rating on Cargo Therapeutics (NASDAQ:CRGX) stock from Buy to Neutral, following the company's announcement to halt its phase II FIRCE-1 clinical trial.

On Thursday, Chardan Capital Markets revised its rating on Cargo Therapeutics (NASDAQ:CRGX) stock from Buy to Neutral, following the company's announcement to halt its phase II FIRCE-1 clinical trial.

Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger ...

Xilio Therapeutics Inc (XLO) stock saw a decline, ending the day at $0.89 which represents a decrease of $-0.38 or -29.92% from the prior close of $1.27. The stock opened at $0.96 and touched a low of ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy recommendation. Analyst Price Forecast Suggests 277.88% Upside As of ...

Along with the evaluation of strategic alternatives, Eyenovia continues to progress development of its advanced Optejet device and is exploring options for use as both a consumer “user-filled” product ...